Research programme: coeliac disease therapy - Avaxia

Drug Profile

Research programme: coeliac disease therapy - Avaxia

Alternative Names: AVX-176; Oral anti-gluten antibodies

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Avaxia Biologics
  • Class Polyclonal antibodies
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coeliac disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Coeliac disease in USA (PO)
  • 10 Mar 2011 Avaxia Biologics receives SBIR grant from US National Institutes of Health for phase I antibody development in Coeliac disease
  • 28 Jun 2010 Avaxia Biologics receives grant from the Massachusetts Life Sciences Center for antibody development in Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top